Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I study of Anti-CD123 CAR-T cell therapy

Next Previous
X
Search
Trial Profile

A phase I study of Anti-CD123 CAR-T cell therapy

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 15 Dec 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anti-CD123 CAR-T cells-Sorrento Therapeutics (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; First in man

    • Most Recent Events

    • 15 Dec 2016 New trial record
    • 01 Dec 2016 According to a Sorrento Therapeutics media release, the company plans to file an Investigational New Drug Application (IND) in the first half of 2017 and trial initiation is expected in the second half of 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top